October is Breast Cancer Awareness Month. The pink ribbon has done extraordinary work raising visibility, but it has also flattened breast health into a single conversation about detection. A mammogram tells you what is there today. It cannot tell you what is coming. For that, you need markers that most women have never been offered.
This session covers breast health as a full-system conversation, not a single-imaging event. We’ll walk through what your standard mammogram and clinical breast exam actually measure, what emerging assessments can add, and how hormone metabolism, breast density, and genetic risk fit together in a complete picture. If you have dense breast tissue, a family history, or hormone-related concerns, this session gives you the vocabulary to advocate for the assessments you actually need.
Standard of care markers we’ll cover include mammography and clinical breast exam protocols, breast density reporting standards, and standard hormonal workup. Emerging markers include the 2:16 alpha-hydroxyestrogen ratio, 4-hydroxyestrone measurement, estrogen metabolism panels, breast MRI criteria for high-risk women, MammaPrint and Oncotype DX when relevant, and the expanded genetic panel beyond BRCA 1 and 2.
You’ll leave with a clear framework for the breast health conversation across the next decade of your life, the specific questions to bring to your physician about your personal risk profile, and understanding of which additional assessments are worth pursuing.
